Psychiatric illness associated with amphetamines and other stimulants;Designerdrogen im psychiatrischen kontext

Psychiatrische Praxis

Volumn 27, Issue 4, 2000, Pages 203-

  Fischer, Roman B ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DRUG ABUSE; HALLUCINATION; HUMAN; PSYCHOSIS;

ADULT; AMNESIA; AMPHETAMINES; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DESIGNER DRUGS; DIAGNOSIS, DIFFERENTIAL; HALLUCINATIONS; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHOSES, SUBSTANCE-INDUCED; RISPERIDONE; SCHIZOPHRENIA;

EID: 0343963062     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Schuster P, Lieb R, Lamertz C, Wittchen HU. Is the use of ecstasy and hallucinogens increasing? Eur Addict Res 1998; 4 (1-2): 75-82
2. Kuntze MF. Ecstasy und Rente. Psychiat Prax 1998; 25 (3): 154
3. Jha A, Fourie H. Risperidone treatment of amphetamine psychosis. Br J Psychiatry 1999; 174: 366
4. Thomasius R (Hrsg). Ecstasy-Wirkungen, Risiken, Interventionen. Stuttgart: Enke, 1999: 61 f
5. Yui K et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry 1999; 4 (6): 512-523
6. Mc Guire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA. BMJ 1991; 302: 697